U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07234032) titled 'An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)' on Nov. 14.
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Study Start Date: April 01, 2026
Study Type: INTERVENTIONAL
Condition:
Pulmonary Hypertension
Interstitial Lung Disease
Intervention:
DRUG: Treprostinil Palmitil Inhalation Powder
Oral inhalation using a capsule-based dry powder.
DRUG: Placebo
Oral inhal...